Optie A:
Klik op de rechtermuisknop op de link en selecteer de optie “linkadres kopiëren”
Optie B:
Deel de link per e-mail
Link delen

Tip

Swipe om te navigeren naar een ander artikel

14-08-2018 | Original Paper

A Randomized, Placebo-Controlled, Blinded, Crossover, Pilot Study of the Effects of Dextromethorphan/Quinidine for the Treatment of Neurobehavioral Symptoms in Adults with Autism

Tijdschrift:: Journal of Autism and Developmental Disorders

Auteurs:: Michael Chez, Shawn Kile, Christopher Lepage, Carol Parise, Bobbie Benabides, Andrea Hankins

» Toegang tot de volledige tekst krijgen

Belangrijke opmerkingen

This work was previously presented in part as Poster Number 213 at the American Academy of Neurology meeting April 22–28 2017 in Boston, MA, but it has not been published elsewhere.

Abstract

Prior studies have demonstrated successful irritability treatment using dopaminergic antagonists in autistic patients. The purpose of this pilot study was to assess the effect of dextromethorphan/quinidine (DM/Q) in autistic adults (18–60 years of age). This was a randomized, blinded, crossover, study of 14 patients randomized to DM/Q or a placebo for 8 weeks, washed out for 4 weeks, then crossed over to the opposite treatment. There were no serious adverse events. Subjects were significantly lower on the Aberrant Behavioral Checklist for Irritability (ABC-IR) (F_1,10 = 7.42; p = 0.021). Improvements in aggression and Clinical Global Impression were also seen. The findings suggest that DM/Q is well-tolerated and associated with improvements in irritability and aggression in adults with autism.

Log in om toegang te krijgen

Hier inloggen

Met onderstaand(e) abonnement(en) heeft u direct toegang:

BSL Psychologie Totaal

Met BSL Psychologie Totaal blijft u als professional steeds op de hoogte van de nieuwste ontwikkelingen binnen uw vak. Met het online abonnement heeft u toegang tot een groot aantal boeken, protocollen, vaktijdschriften en e-learnings op het gebied van psychologie en psychiatrie. Zo kunt u op uw gemak en wanneer het u het beste uitkomt verdiepen in uw vakgebied.

Meer informatie

Aman, M., Rettiganti, M., Nagaraja, H. N., Hollway, J. A., McCracken, J., McDougle, C. J., et al. (2015). Tolerability, safety, and benefits of risperidone in children and adolescents with autism: 21-month follow-up after 8-week placebo-controlled trial. Journal of Child and Adolescent Psychopharmacology, 25(6), 482–493. https://doi.org/10.1089/cap.2015.0005. CrossRefPubMedPubMedCentral

Baio, J., Wiggins, L., Christensen, D. L., Maenner, M. J., Daniels, J., Warren, Z., et al. (2018). Prevalence of autism spectrum disorder among children aged 8 years—Autism and developmental disabilities monitoring network, 11 sites, United States, 2014. MMWR Surveillance Summaries, 67(6), 1–23. https://doi.org/10.15585/mmwr.ss6706a1. CrossRefPubMedCentral

Bauman, M., & Kemper, T. L. (1985). Histoanatomic observations of the brain in early infantile autism. Neurology, 35(6), 866–874. CrossRefPubMed

Bauman, M. L., & Kemper, T. L. (1994). The neurobiology of autism. Baltimore: Johns Hopkins University Press.

Chez, M. G., Burton, Q., Dowling, T., Chang, M., Khanna, P., & Kramer, C. (2007). Memantine as adjunctive therapy in children diagnosed with autistic spectrum disorders: An observation of initial clinical response and maintenance tolerability. Journal of Child Neurology, 22(5), 574–579. CrossRefPubMed

Hammond, F. M., Alexander, D. N., Cutler, A. J., D’Amico, S., Doody, R. S., Sauve, W., et al. (2016). PRISM II: An open-label study to assess effectiveness of dextromethorphan/quinidine for pseudobulbar affect in patients with dementia, stroke or traumatic brain injury. BMC Neurology, 16, 89. https://doi.org/10.1186/s12883-016-0609-0. CrossRefPubMedPubMedCentral

Hellings, J. A., Nickel, E. J., Weckbaugh, M., McCarter, K., Mosier, M., & Schroeder, S. R. (2005). The overt aggression scale for rating aggression in outpatient youth with autistic disorder: Preliminary findings. Journal of Neuropsychiatry and Clinical Neurosciences, 17(1), 29–35. CrossRefPubMed

IBM SPSS Statistics for Windows, (2012). vol 21.0. Armonk: IBM Corp.

King, B. H., Wright, D. M., Handen, B. L., Sikich, L., Zimmerman, A. W., McMahon, W., et al. (2001). Double-blind, placebo-controlled study of amantadine hydrochloride in the treatment of children with autistic disorder. Journal of the American Academy of Child and Adolescent Psychiatry, 40(6), 658–665. CrossRefPubMed

Marcus, R. N., Owen, R., Kamen, L., Manos, G., McQuade, R. D., Carson, W. H., et al. (2009). A placebo-controlled, fixed-dose study of aripiprazole in children and adolescents with irritability associated with autistic disorder. Journal of the American Academy of Child and Adolescent Psychiatry, 48(11), 1110–1119. https://doi.org/10.1097/CHI.0b013e3181b76658. CrossRefPubMed

Margari, L., Matera, E., Craig, F., Petruzzelli, M. G., Palmieri, V. O., Pastore, A., et al. (2013). Tolerability and safety profile of risperidone in a sample of children and adolescents. International Clinical Psychopharmacology, 28(4), 177–183. https://doi.org/10.1097/YIC.0b013e328362497b. PubMed

McCracken, J. T., McGough, J., Shah, B., Cronin, P., Hong, D., Aman, M. G., et al. (2002). Risperidone in children with autism and serious behavioral problems. New England Journal of Medicine, 347(5), 314–321. https://doi.org/10.1056/NEJMoa013171. CrossRefPubMed

Orsolini, L., Tomasetti, C., Valchera, A., Vecchiotti, R., Matarazzo, I., Vellante, F., et al. (2016). An update of safety of clinically used atypical antipsychotics. Expert Opinion on Drug Safety, 15(10), 1329–1347. https://doi.org/10.1080/14740338.2016.1201475. CrossRefPubMed

Owen, R., Sikich, L., Marcus, R. N., Corey-Lisle, P., Manos, G., McQuade, R. D., et al. (2009). Aripiprazole in the treatment of irritability in children and adolescents with autistic disorder. Pediatrics, 124(6), 1533–1540. CrossRefPubMed

Pattee, G. L., Wymer, J. P., Lomen-Hoerth, C., Appel, S. H., Formella, A. E., & Pope, L. E. (2014). An open-label multicenter study to assess the safety of dextromethorphan/quinidine in patients with pseudobulbar affect associated with a range of underlying neurological conditions. Current Medical Research and Opinion, 30(11), 2255–2265. https://doi.org/10.1185/03007995.2014.940040. CrossRefPubMedPubMedCentral

Perry, E. K., Lee, M. L., Martin-Ruiz, C. M., Court, J. A., Volsen, S. G., Merrit, J., et al. (2001). Cholinergic activity in autism: Abnormalities in the cerebral cortex and basal forebrain. American Journal of Psychiatry, 158(7), 1058–1066. CrossRefPubMed

Pioro, E. P. (2014). Review of dextromethorphan 20 mg/quinidine 10 mg (NUEDEXTA((R))) for pseudobulbar affect. Neurology and Therapy, 3(1), 15–28. https://doi.org/10.1007/s40120-014-0018-5. CrossRefPubMedPubMedCentral

Posey, D. J., Kem, D. L., Swiezy, N. B., Sweeten, T. L., Wiegand, R. E., & McDougle, C. J. (2004). A pilot study of D-cycloserine in subjects with autistic disorder. American Journal of Psychiatry, 161(11), 2115–2117. CrossRefPubMed

Purcell, A. E., Jeon, O. H., Zimmerman, A. W., Blue, M. E., & Pevsner, J. (2001). Postmortem brain abnormalities of the glutamate neurotransmitter system in autism. Neurology, 57(9), 1618–1628. CrossRefPubMed

Schreibman, L. (2000). Intensive behavioral/psychoeducational treatments for autism: Research needs and future directions. Journal of Autism Developmental Disorders, 30(5), 373–378. CrossRefPubMed

Woodard, C., Groden, J., Goodwin, M., & Bodfish, J. (2007). A placebo double-blind pilot study of dextromethorphan for problematic behaviors in children with autism. Autism, 11(1), 29–41. https://doi.org/10.1177/1362361307070989. CrossRefPubMed

Woodard, C., Groden, J., Goodwin, M., Shanower, C., & Bianco, J. (2005). The treatment of the behavioral sequelae of autism with dextromethorphan: A case report. Journal of Autism Developmental Disorders, 35(4), 515–518. https://doi.org/10.1007/s10803-005-5041-z. CrossRefPubMed

Zimmerman, A. (1991). Treating autism and other developmental disorders in children with NMDA receptor antagonists. Patent 4,994,467. https://patentimages.storage.googleapis.com/b7/68/af/6bd5da44812183/US4994467.pdf.

Titel: A Randomized, Placebo-Controlled, Blinded, Crossover, Pilot Study of the Effects of Dextromethorphan/Quinidine for the Treatment of Neurobehavioral Symptoms in Adults with Autism
Auteurs:: Michael Chez
Shawn Kile
Christopher Lepage
Carol Parise
Bobbie Benabides
Andrea Hankins
Publicatiedatum: 14-08-2018
DOI: https://doi.org/10.1007/s10803-018-3703-x
Uitgeverij: Springer US
Tijdschrift: Journal of Autism and Developmental Disorders
Print ISSN: 0162-3257
Elektronisch ISSN: 1573-3432

Bohn Stafleu van Loghum

Deel dit onderdeel of sectie (kopieer de link)

Tip

Swipe om te navigeren naar een ander artikel

Abstract

Log in om toegang te krijgen

Met onderstaand(e) abonnement(en) heeft u direct toegang:

BSL Psychologie Totaal